Peptonic signs distributor agreement with Windsor Pharmaceutical
Peptonic Medical (publ) today informed the company has signed an exclusive distributor agreement for Central Amerika with Windsor Pharmaceutical concerning the companys vaginal self tests
Peptonic has signed an exclusive distributor agreement with Windsor Pharmaceutical for countries in Central America. The contract spans over four years and includes Peptonic Medical self tests for vaginal infections and amniotic leakage. The products will be sold under Windsor Pharmaceuticals own brand Amniotest.
Windsor Pharmaceutical is a pharmaceutical company founded 2016 with a specific focus on women’s health in Central America. The company has an extensive experience of registering as well as getting reimbursement for its range of products.
- We are very pleased with having landed an agreement with Windsor Pharmaceutical. That the products have gotten reimbursement and will be readily available for women with an early launch is very exciting, say’s Erik Sundquist CEO of Peptonic Medical
- Peptonic Medical has a very interesting range of self tests which we are very excited to build the business for in a region where we have very extensive experience of women’s health and hospital health care systems, says Christian Naumann, CEO and Founder of Windsor Pharmaceutical
VagiVital VS is a clinically proven self test that diagnoses vaginal infection with 92% accuracy. The test is carried out on vaginal fluid and indicates the answer within 30 seconds.
VagiVital AL is a clinically proven self test that can detect amniotic leakage with 97% accuracy. The test consists of a pantyliner with a patented biofilm on its surface. The result is indicated with a color change 15 minutes after the pantyliner has become wet.
Peptonic continues to meet strong interest from international distributors concerning its clinically proven vaginal self tests. The agreement with Windsor is additional evidence that the company’s solutions are sought after and another quality stamp of its medical device products.
The launch is expected in q2 this year.
Erik Sundquist, CEO
Telefon: + 46 722 49 90 43
E-post: erik.sundquist@peptonicmedical.se
ABOUT Peptonic Medical AB
Peptonic is a Swedish innovative biomedical company that conducts research, development and sales of medical treatments and lifestyle products in the field of women's health. Peptonic has divided its operations into two business areas: "Medical Consumer" and "Lifestyle Consumer". The business area "Medical Consumer" is based on clinically proven intimate self-care and constitutes the company's main focus and is sold under the VagiVital brand. The "Lifestyle Consumer" business area consists of lifestyle products with a focus on sustainable menstrual products and is sold under the Lunette brand. The company was founded in 2009 and the stock has been traded since 2014 on Spotlight (www.spotlightstockmarket.com) in Stockholm